COMMUNIQUÉS West-GlobeNewswire

The Association of American Physicians and Surgeons (AAPS) Supports Course Correction on Autism
24/09/2025
TUCSON, Ariz., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In a joint appearance, President Donald Trump, HHS Secretary Robert F. Kennedy, Jr., NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, and CMS Director [...]
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations
24/09/2025
Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR [...]
Booking Health Expands Access to Stage 4 Cancer Treatment in Germany
24/09/2025
Langenfeld, Germany, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Booking Health , a leading medical travel facilitator, has announced the expansion of its oncology services to improve international access to advanced stage 4 [...]
EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025
24/09/2025
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36% of revenue 42% of revenue generated outside France 2025 results impacted by the transfer of [...]
Eurobio Scientific : résultat du 1er semestre 2025
24/09/2025
RESULTAT DU 1 ER SEMESTRE 2025 Chiffre d’affaires en croissance de 10% à 80,7 M€ les produits propriétaires atteignent 36% du CA la part du CA hors France est de 42% Résultats 2025 impacté par le transfert de la [...]
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387,8 M€, en retrait de 5,4% à TCC et périmètre comparable principalement en lien avec la baisse d’activité en France
24/09/2025
Résultats semestriels 2025 Activité et rentabilité Chiffre d’affaires du 1 er semestre : 387,8 M€, en retrait de 5,4% à TCC 1 et périmètre comparable 2 , principalement en lien avec la baisse d’activité en France La [...]
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France
24/09/2025
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER 1 and on a like-for-like basis 2 , mainly due to the decline in activity in France Restated EBITDA margin 3 came out at 12.9%, [...]
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
24/09/2025
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
LUKE Calls for National Partnerships to Help America’s Heroes Flourish
24/09/2025
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- As the American Association of Christian Counselors (AACC) World Conference in Nashville opens, LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing [...]
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
24/09/2025
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be [...]
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
24/09/2025
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to [...]
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
24/09/2025
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose [...]
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
24/09/2025
IMDX to host symposium on Wednesday, September 24 th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting on GraftAssureIQ at [...]
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit
24/09/2025
TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Healthcare must be recognized as the world’s most strategic investment in security, prosperity, and resilience—not as a financial burden—declared H.E. Dr. Majid Alfayyadh, [...]
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
24/09/2025
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject [...]
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
24/09/2025
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 3 rd , 2025 SOUTH SAN FRANCISCO, Calif., Sept. 24, [...]
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
24/09/2025
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Kura Oncology to Participate in Upcoming Investor Conference
24/09/2025
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
24/09/2025
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

Pages